A Phase 1/2 Study of BA3071 in Patients With Solid Tumors (NCT05180799)

🧪 Interventions in This Study

• BA3071 (BIOLOGICAL)
• Nivolumab (BIOLOGICAL)
• Pembrolizumab (BIOLOGICAL)
• Pemetrexed (Alimta) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (12 Sites)

• The Angeles Clinic and Research Institute — Los Angeles, California
• USC Norris Comprehensive Cancer Center — Los Angeles, California
• Piedmont West — Atlanta, Georgia
• Northwest Cancer Centers — Dyer, Indiana
• Morristown Medical Center/Atlantic Health System — Morristown, New Jersey
• Icahn School of Medicine at Mt. Sinai — New York, New York
• University Hospitals Cleveland Medical Center — Cleveland, Ohio
• Providence Cancer Institute — Portland, Oregon
• University of Utah Huntsman Cancer Institute — Salt Lake City, Utah
• Border Medical Oncology Research Unit at Albury Wodonga Regional Cancer Centre — Albury, New South Wales
• Cancer Care Foundation — Miranda, New South Wales
• Cancer Research South Australia — Adelaide, South Australia

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in NSCLC

• Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy — Savannah, Georgia
• A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC — Daphne, Alabama
• Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC — La Jolla, California
• A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care — Boston, Massachusetts
• Study of Oral MRT-2359 in Selected Cancer Patients — Scottsdale, Arizona
• Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations — Phoenix, Arizona

Explore by condition: All NSCLC clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.